

## Telisotuzumab

|           |   |
|-----------|---|
| Cat. No.: | HY-P99391   |
| CAS No.:  | 1781223-80-0  |
| Target:   | Others  |
| Pathway:  | Others  |
| Storage:  | Please store the product under the recommended conditions in the Certificate of Analysis. |

### BIOLOGICAL ACTIVITY

|                    |   |   |
|--------------------|---|---|
| <b>Description</b> | Telisotuzumab (ABT-700) is a human recombinant bivalent antibody, a therapeutic antibody against the hepatocyte growth factor receptor (MET) that binds c-Met with high affinity and inhibits c-Met signaling. Telisotuzumab has antitumor activity <sup>[1]</sup> .  |   |
| <b>In Vitro</b>    | Telisotuzumab (ABT-700) (10 µg/mL, 24 h) inhibits the proliferation of SNU5 cells and leads to an increase in pro-apoptotic Bim and a decrease in anti-apoptotic Bcl-xL, thereby inducing apoptosis <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only.                 |   |
| <b>In Vivo</b>     | Telisotuzumab (ABT-700) (i.p., 2.5-40 mg/kg, twice a week, 90 days) effectively antagonizes constitutively activated c-Met and downstream signaling, thereby inhibiting tumor growth in SCID mice with Hs746T cells <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |   |
|                    | Animal Model:   | SCID mice with Hs746T cells <sup>[1]</sup>  |
|                    | Dosage:   | 2.5-40 mg/kg  |
|                    | Administration:   | i.p., twice a week, 90 days   |
|                    | Result:   | Reduced total and phosphorylated c-Met as well as phosphorylated Akt and Erk.<br>Complete tumor regression at doses above 10 mg/kg but no effective inhibition of tumor growth at doses below 5mg/kg. |

### REFERENCES

[1]. Jieyi Wang, et al. Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification. BMC Cancer. 2016 Feb 16;16:105.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA